Guided Therapy Systems Keeps Options Open On Tissue Regen Device
Guided Therapy Systems CEO Michael Slayton, PhD, has a history of breaking innovative medical technology, with a primary focus on diagnostic and therapeutic ultrasound applications. He tells In Vivo about the 22-year engineering journey that has led him and the company he founded to the cusp of market launch of a non-invasive tissue regeneration device for musculoskeletal injuries.
You may also be interested in...
New Enterprise Associates registered one of its biggest returns ever when Merz agreed to pay up to $600 million for aesthetics company Ulthera. CEO Matthew Likens and lead investor Justin Klein, MD, discuss specifics about the blockbuster deal.
The latest guidance from the UK devices regulator fills in some of the information gaps for companies addressing the Northern Ireland and EU27 markets after this year, seen through the lens of Brexit.
Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.